About
About Q-linea AB (publ)
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom and European Union. The company offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. It also develops Podler, a portable blood culture unit for incubating and detecting growth in blood bottles. The company serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.
Visit company website
5 years, 5 months ago
Q-linea AB (publ) is currently in a long term downtrend where the price is trading 6.8% below its 200 day moving average.
From a valuation standpoint, the stock is 12.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1479.4.
Q-linea AB (publ)'s total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 21.5% to $-49M since the same quarter in the previous year.
Finally, its free cash flow fell by 40.1% to $-78M since the same quarter in the previous year.
Based on the above factors, Q-linea AB (publ) gets an overall score of 1/5.